Why Alterity Therapeutics Limited’s (ATHE) Stock Is Up 6.71%
As of Wednesday, September 16, Alterity Therapeutics Limited’s ATHE share price has surged by 6.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Alterity Therapeutics Limited (ATHE)
Alterity Therapeutics Limited ATHE
$3.72
0.22
6.29%
September 16, 2026 11:44:11 AM
EST
Volume: 6,030
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Commentary & Analysis
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 5.29%
As of Monday, September 14, Alterity Therapeutics Limited’s ATHE share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Up 5.35%
As of Friday, September 11, Alterity Therapeutics Limited’s ATHE share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 5.56%
As of Thursday, September 10, Alterity Therapeutics Limited’s ATHE share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Up 5.01%
As of Thursday, July 16, Alterity Therapeutics Limited’s ATHE share price has surged by 5.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $66.8 | $262.9 | 18% |
|
| Shares Out (Mil) | 150.4 | 54.4 | 71% |
|
| Institutional Ownership | 91.4% | 92.9% | 60% |
|
| Float (Mil) | 176.1 | 41.5 | 71% |
|
| Beta | -0.04 | 0.94 | 5% |
|
| Avg Daily Volume (000s) | 20 | 496 | 20% |
|
| Price Change (52-week) |
(28.3%) | 54.5% | 27% |
|
| Growth | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (5.4%) | 14.1% | 8% |
|
| Net Income (5yr) | (7.1%) | (10.1%) | 32% |
|
| EPS (5yr) | 25.6% | 15.8% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (48.6%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($16) | ($43) | 25% |
|
| EPS (TTM) | ($0.077) | ($1.500) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $2 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $50 | $179 | 16% |
|
| Valuation | ATHE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 25.00 | 2.56 | 97% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.7% | 68.2% | 94% |
|
| Net Margin | (648.2%) | (73.0%) | 1% |
|
| ROA | (52.2%) | (47.9%) | 11% |
|
| ROE | (56.4%) | (55.0%) | 14% |
|
| Liabilities to Assets | 7.2% | 29.4% | 4% |
|
| F-Score | 3 | 2 | 18% |
|
Alterity Therapeutics Limited did not pass any screens on 9/15/2026.
